The Gulf conflict has disrupted global supply chains, pushed...
REITs have changed the way commercial real estate is owned a...
What really powers the cloud? Behind every Google search, A...
What really powers the cloud? Behind every Google search, A...
Luxury real estate is one of the most talked-about segments ...
Tavexia Lifecare Limited has entered the pharmaceutical sector as a new business vertical, expanding beyond its existing lifecare operations. The Mumbai-based company said it will evaluate opportunities across pharmaceutical products, Active Pharmaceutical Ingredients (APIs), intermediates, specialty chemicals, nutraceuticals and related manufacturing activities. The move is intended to diversify its business portfolio and establish additional avenues for long-term growth while retaining lifecare as its core business. Tavexia’s expansion comes as India’s pharmaceutical industry continues to grow, with the domestic market estimated at around USD 60 billion and projected to reach approximately USD 130 billion by 2030. Pharmaceutical exports from India stood at around USD 30.47 billion in FY2024-25, according to the company.
Tavexia Lifecare Limited has expanded into the pharmaceutical sector as a new growth vertical, with the company announcing on August 26 that it will assess opportunities across pharmaceutical products, APIs, intermediates, specialty chemicals, nutraceuticals and related manufacturing activities.
The move is aimed at diversifying Tavexia’s business portfolio and developing additional avenues for long-term growth, while its existing lifecare operations will continue to remain central to the company’s business. The pharmaceutical vertical will allow Tavexia to assess opportunities across multiple stages of the healthcare and pharmaceutical value chain.
The company said the new vertical is intended to complement its existing operations and provide a wider platform for evaluating product development, strategic partnerships and manufacturing opportunities. Tavexia will assess potential opportunities based on market conditions, commercial viability and their longer-term strategic value.
The expansion comes against the backdrop of growth in India’s pharmaceutical industry. The country’s pharmaceutical market is currently estimated at around USD 60 billion and is projected to reach approximately USD 130 billion by 2030. India’s pharmaceutical exports were valued at around USD 30.47 billion during FY2024-25, highlighting the sector’s role in the country’s participation in global healthcare and pharmaceutical supply chains.
Mit Tarunkumar Brahmbhatt, chairman and managing director of Tavexia Lifecare, said the company’s core lifecare business would remain central to its growth strategy, while pharmaceuticals represented an extension of its presence across the wider healthcare ecosystem. He said the company sees opportunities in India’s pharmaceutical sector to develop an additional growth engine alongside its existing operations.
Brahmbhatt added that Tavexia would focus on disciplined execution, developing sustainable business capabilities and creating long-term value for shareholders and other stakeholders.
The company plans to continue strengthening its existing lifecare operations while simultaneously evaluating pharmaceutical opportunities. Its proposed activities span finished pharmaceutical products, APIs, intermediates, specialty chemicals and nutraceuticals, as well as potential manufacturing-related opportunities.
Tavexia said it intends to adopt a calibrated approach to the new business vertical, with the focus on building sustainable capabilities rather than immediately expanding across the entire pharmaceutical value chain. The company expects the addition of pharmaceuticals to broaden its addressable market while creating a more diversified platform for future business development.
The move therefore adds a new business vertical to Tavexia’s existing lifecare operations, with future investments and initiatives expected to be assessed according to market potential, commercial feasibility and strategic relevance.
17th Nov, 2026
17th Nov, 2026
17th Nov, 2026
17th Nov, 2026
17th Nov, 2026